From the first moment I discovered I had been diagnosed with DIABETES, I joined a HUGE “club” that has been rapidly expanding since it stopped being a death sentence in the early 20th Century. Currently, there are about HALF A BILLION PEOPLE who have Type 2 Diabetes. For the past 3500 years – dating back to Ancient Egypt – people have suffered from diabetes. Well, I’m one of them now… Not one to shut up for any known reason, I added a section to this blog…
Every month, I’ll be highlighting Diabetes research that is going on RIGHT NOW! Harvested from different websites, journals and podcasts, I’ll translate them into understandable English and share them with you. Today: Repairing the Pancreas!
While the headline is from a report from China published this past May, the DREAM of restarting a pancreas damaged enough to initiate Type 2 diabetes has been around at least since 2011.
Today, there is not only hope that this might happen, but AT LEAST ONE person whose Type 2 diabetes was reversed using his own treated stem cells to regrow pancreas cells in large enough numbers to reinitiate his body’s production of the correct amount of insulin.
In the September 2011 issue of Genome Medicine, the author wrote: “Stem cells hold great promise for pancreatic beta cell replacement therapy for diabetes. In type 1 diabetes, beta cells are mostly destroyed, and in type 2 diabetes beta cell numbers are reduced by 40% to 60%. The proof-of-principle that cellular transplants of pancreatic islets, which contain insulin-secreting beta cells, can reverse the hyperglycemia of type 1 diabetes has been established, and there is now a need to find an adequate source of islet cells.” At this time, the only real hope was using human embryonic stem cells.
Ten years later, in Amsterdam, the research team discovered that, “all acinar and ductal cells – cells that produce digestive enzymes and transport them to the gut – actually contribute to [the] process [of repairing pancreatic cells]. All cells in the pancreas that produce digestive enzymes and transport them to the gut can contribute to its regenerative capacity.”
The initial study was fifteen YEARS ago, and in genetic research, that’s like decades. The work in Amsterdam took place in 2021. Today, researchers in Shanghai, China, “Utilizing the patient’s own endoderm stem cells (EnSCs), they were able to differentiate these stem cells into functional pancreatic islet cells – cells in the pancreas that secrete hormones, including insulin and glucagon, that help regulate blood sugar levels.”
What does this mean? It means the team in China found that they could use…the patient’s own “undifferentiated cells, found throughout the body after development, that multiply by cell division to normally replenish dying cells and regenerate damaged tissues...” All of us have them, they’re what heals the skin or any kind of internal damage we suffer during routine surgery. These stem cells do not depend on the use of fetal tissue. “[researchers] were able to differentiate [the patient’s own] stem cells into functional pancreatic islet cells – cells in the pancreas that secrete hormones, including insulin and glucagon, that help regulate blood sugar levels then transplant them into the patient’s pancreas.”
What happened? “Following a kidney transplant in 2017, the patient experienced a decline in pancreatic islet function, necessitating daily multi-dose insulin injection.” His stem cells were removed and grown, and after they injected them in the pancreas…”the patient achieved insulin independence within a mere 11 weeks post-transplantation. Oral medication for diabetes management was gradually reduced and ultimately discontinued a year later. Follow-up examinations conducted over a prolonged period revealed restored pancreatic function, with the patient no longer requiring insulin or oral or injectable medications that had become in short supply due to their use as weight-reduction drugs. Additionally, normal kidney function was maintained, suggesting a potential long-term cure for both type 2 diabetes and the underlying complications associated with the initial kidney transplant.”
NOTE! The procedure had been successfully attempted on this single patient at the time of the publication of the article in May of 2024. There may be others in the pipeline; but there’s no further evidence of any wide-spread study or a call for volunteers.
What it SHOULD inspire is HOPE. If not for me, then for anyone else in the future who finds themselves facing Type 2 diabetes for a real cure in our lifetime!
Links: https://cells4life.com/2024/05/stem-cell-therapy-achieves-cure-for-type-2-diabetes/, https://nyscf.org/resources/uncovering-the-unique-way-the-pancreas-regenerates/, https://genomemedicine.biomedcentral.com/articles/10.1186/gm277; https://nyscf.org/resources/uncovering-the-unique-way-the-pancreas-regenerates/ Image: https://asploro.com/wp-content/uploads/2019/12/Diabetes-Research_Open-Access.jpg
For the first time since I started this blog eleven years ago, it’s going to be about me. I was diagnosed with Type 2 Diabetes two weeks ago. While people are happy to talk about their experiences with diabetes, I WASN’T comfortable with talking about diabetes. My wife is Type 2, as are several friends of ours. The “other Type” of diabetes was what caused the death of my Best Man a year after my wife and I got married. He was diagnosed with diabetes when he was a kid. It was called Juvenile Diabetes then. Today it’s Type 1. Since then, I haven’t WANTED to talk about diabetes at all. But…for my own education and maybe helping someone else, and not one to shut up for any known reason, I’m reopening my blog rather than starting a new one. I MAY take a pause and write about Breast Cancer or Alzheimer’s as medical headlines dictate; but this time I’m going to drag anyone along who wants to join my HIGHLY RELUCTANT journey toward better understanding of my life with Type 2 Diabetes. You’re Welcome to join me!
Dr. Elbert Huang, director of the UChicago Center for Chronic Disease Research and Policy, wrote in April of 2024: “The exclusion of older adults from early [Type 2 diabetes] trials stems in part from the complexity of aging, which can include multiple diseases and medical conditions occurring simultaneously. However, their absence meant the studies essentially did not represent how diabetes presents in the real world. “The majority of people with diabetes are over 65, so our evidence was not based [on data from those people].”
Startlingly, I now find myself in the class of people who have not appeared to matter to the medical establishment. We’ve lost perhaps a decade of time in looking for treatments for older adults who have Type 2 diabetes. How many people – I ask this sarcastically, because what do people who are more familiar with paper letters than cellphones and are usually over 65 REALLY matter in this 5G world [which is, I read, how FAST we get our internet information. (3G was born in 2008 and let us get our data at a rate of 3 megabytes per second. 4G boosted that to 14 megabytes pers second (MBPS). 5G boosted that to 100 MBPS to its SIX AND A HALF BILLION USERS.]
Clearly, not worth talking about.
That appears to be changing. Dr. Huang was of the opinion that “…[to the medical world] the sickest patients should get less medication because they're [un]likely to…benefit from [them]…it goes back to insulin: the original trial comparing moderate and intensive glucose control…was conducted during a time when the number of available drug classes were very limited [ie: no Glipizide, Metformin, Ozempic, or any of the other modern treatments]...that trial showed that people do better with lower blood sugar, but you had to live for at least 10 years to see the benefit.” The subtext there of course, is “and all these old people won’t make it that long, so why bother studying them because NOTHING IS GOING TO CHANGE.
Huang goes on to say, “…cancer and heart disease can disqualify people from participating in [drug treatment] trials. Yet…patients with such conditions are representative of average geriatric diabetes patients, and physicians must be able to treat them.”
Huang concludes: “For many years people have talked quite vaguely about older patients, saying, ‘This older patient is complex,’ ‘This older patient is frail. Now we have tools that are much more specific and reproducible,” Huang said. “And now we can with greater specificity say who is missing from the trials, which could help us reexamine trial data and reshape how we design trials in the future.”
A recent result of this changed attitude led to Mounjaro and Zepbound: “A key study of [tirzepatide, the main ingredient of those two “Brand Name” drugs, discovered that there was] a significant reduction in the risk of progression to type 2 diabetes in adults with pre-diabetes and obesity or overweight…[which] achieved significant results, demonstrating a 93-94% reduction in risk of progression to type 2 diabetes [compared to placebo].”
The implication is that testing the drug on people 65+ discovered that not only could we TREAT Type 2 diabetes, we can now PREVENT it altogether – and avoid the concurrent drain on the cash-payout of the massive profit-driven insurance companies that are required by law to cover us “Golden-Agers”!
Source: https://biologicalsciences.uchicago.edu/news/new-diabetes-drugs-prompt-reassessment-care-strategies-older-patients; https://investor.lilly.com/news-releases/news-release-details/tirzepatide-reduced-risk-developing-type-2-diabetes-94-adults Image: https://www.hcd.com/wp-content/uploads/2021/01/living-well-with-diabetes.jpg
